Top Avian Influenza Vaccine Companies

Global Avian Influenza Vaccine Market size was valued at USD 152.01 Billion in 2024 and is poised to grow from USD 158.39 Billion in 2025 to USD 220.13 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026–2033).

The competitive environment of the Global Avian Influenza Vaccine Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. 'Sanofi (France) ', 'GlaxoSmithKline (GSK) (United Kingdom) ', 'Moderna Inc. (United States) ', 'Pfizer Inc. (United States) ', 'AstraZeneca (United Kingdom) ', 'Novavax, Inc. (United States) ', 'Vaxart, Inc. (United States) ', 'BioNTech SE (Germany) ', 'Sinovac Biotech Ltd. (China) ', 'Bharat Biotech International Ltd. (India) ', 'Serum Institute of India Pvt. Ltd. (India) ', 'Daiichi Sankyo Company, Limited (Japan) ', 'Mitsubishi Tanabe Pharma Corporation (Japan) ', 'Seqirus UK Limited (United Kingdom) ', 'Emergent BioSolutions Inc. (United States) ', 'Johnson & Johnson (United States) ', 'Abbott Laboratories (United States) ', 'Roche Holding AG (Switzerland) ', 'Merck & Co., Inc. (United States)'

Avian influenza can be defined as a disease caused by avian influenza virus type-A. This virus is commonly found in waterfowl and can infect domestic chickens and other bird species. Based on viral surface proteins, subtypes of influenza type A viruses can be classified into neuraminidase (NA) and hemagglutinin (HA). Based on their molecular characteristics and ability to cause disease and death in chicken avian influenza viruses are classified as highly pathogenic and low pathogenicity but both in poultry, high prevalence is reported. Nonpathogenic bird flu viruses show no signs of illness. Only mild diseases such as egg decline and wildflies show it. However, infection with the highly pathogenic influenza virus is associated with high mortality.

Along with Israel, China, India and South Korea have the highest number of bird flu viruses in Asia-Pacific. This is followed by rapid supply chain improvements and a growing R&D infrastructure through supportive government policies.

The global avian influenza vaccine market is dominated by Asia Pacific. This can be attributed to increased poultry production and increasing outbreaks of bird flu in the region. China produced 13,900 thousand metric tons of poultry meat in 2022, according to a recent Foreign Agricultural Service/USDA report, it is estimated that the U.S. will exhibit significant market growth due to growing meat and poultry industry, increasing animal health expenditure.